Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.172
+0.002 (0.99%)
Nov 21, 2024, 1:34 PM EST - Market open
Citius Pharmaceuticals Stock Forecast
CTXR's stock price has decreased by -77.83% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for CTXR stock have an average target of 5.00, with a low estimate of 4.00 and a high estimate of 6.00. The average target predicts an increase of 2,813.75% from the current stock price of 0.17.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CTXR stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +2,231.00% | Nov 12, 2024 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +3,396.50% | Nov 11, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +3,396.50% | Aug 19, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +3,396.50% | Aug 8, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +3,396.50% | Aug 5, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
88.16M
EPS This Year
-0.20
from -0.22
EPS Next Year
0.19
from -0.20
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | 127.4M | 289.0M | |||
| Avg | n/a | 88.2M | 242.4M | |||
| Low | n/a | 45.0M | 196.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | 227.9% | |||
| Avg | - | - | 175.0% | |||
| Low | - | - | 122.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.21 | 0.20 | 0.80 |
| Avg | -0.20 | 0.19 | 0.78 |
| Low | -0.20 | 0.19 | 0.74 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | 311.8% |
| Avg | - | - | 300.0% |
| Low | - | - | 284.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.